Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna Shares Lose Momentum After Meteoric Rise: Here's Why

by Zacks Equity Research

The encouraging progress with mRNA-based coronavirus vaccine drives meteoric rise in Moderna's (MRNA) shares. However, a rumored concern leads to correction.

Zacks Equity Research

Company News for Jul 6, 2020

by Zacks Equity Research

Companies In The News Are: TSLA, ALK, MRNA, BA.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen

by Sweta Jaiswal, FRM

As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.

Zacks Equity Research

Pfizer Reports Encouarging Data From Coronavirus Program

by Zacks Equity Research

Pfizer (PFE) announces promising preliminary data on a vaccine candidate from its early-stage coronavirus program under which it is developing four mRNA-based vaccine candidates.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Moderna (MRNA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Kinjel Shah headshot

FDA Issues Guidance for Coronavirus Vaccine Developers

by Kinjel Shah

Around a dozen companies are developing a vaccine for the deadly coronavirus disease.

Sanghamitra Saha headshot

Investing Strategies for 2H Amid Coronavirus Resurgence

by Sanghamitra Saha

Investors should prepare well before investing in 2H as many market watchers are suspecting rising volatility ahead.

Zacks Equity Research

Vaxart's Oral Coronavirus Vaccine Candidate Gets Chosen by OWS

by Zacks Equity Research

Vaxart's (VXRT) oral COVID-19 vaccine candidate is picked for a non-human primate challenge study as part of the Operation Warp Speed initiative to rapidly develop a vaccine against SARS-CoV-2.

Sanghamitra Saha headshot

Top Leveraged ETFs of Last Week

by Sanghamitra Saha

Leveraged gold miners and treasury ETFs gained last week despite a market crash.

Zacks Equity Research

Moderna (MRNA) Stock Moves -1.16%: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $61.28, marking a -1.16% move from the previous day.